Processa Pharmaceuticals Inc (NASDAQ: PCSA) kicked off on Tuesday, up 7.36% from the previous trading day, before settling in for the closing price of $0.28. Over the past 52 weeks, PCSA has traded in a range of $0.15-$1.50.
During the last 5-year period, the sales growth of Healthcare Sector giant was 22.65%. While this was happening, its average annual earnings per share was recorded 89.15%. With a float of $49.24 million, this company’s outstanding shares have now reached $52.86 million.
Let’s determine the extent of company efficiency that accounts for 10 employees.
Processa Pharmaceuticals Inc (PCSA) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Processa Pharmaceuticals Inc is 13.07%, while institutional ownership is 3.14%. The most recent insider transaction that took place on Jan 27 ’25, was worth 9,889. In this transaction Director of this company bought 12,400 shares at a rate of $0.80, taking the stock ownership to the 12,400 shares. Before that another transaction happened on Jan 27 ’25, when Company’s Chief Executive Officer bought 87,200 for $0.80, making the entire transaction worth $69,542. This insider now owns 87,200 shares in total.
Processa Pharmaceuticals Inc (PCSA) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.74 earnings per share (EPS), higher than consensus estimate (set at -0.92) by 0.18.
According to the Wall Street analysts, stocks earnings will be around 89.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.14% during the next five years compared to 22.65% growth over the previous five years of trading.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Trading Performance Indicators
Take a look at Processa Pharmaceuticals Inc’s (PCSA) current performance indicators. Last quarter, stock had a quick ratio of 3.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.36, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Processa Pharmaceuticals Inc (PCSA)
Looking closely at Processa Pharmaceuticals Inc (NASDAQ: PCSA), its last 5-days average volume was 0.86 million, which is a drop from its year-to-date volume of 8.64 million. As of the previous 9 days, the stock’s Stochastic %D was 90.84%.
During the past 100 days, Processa Pharmaceuticals Inc’s (PCSA) raw stochastic average was set at 35.77%, which indicates a significant decrease from 98.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0239 in the past 14 days, which was lower than the 0.0307 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3094, while its 200-day Moving Average is $0.2840. However, in the short run, Processa Pharmaceuticals Inc’s stock first resistance to watch stands at $0.3156. Second resistance stands at $0.3262. The third major resistance level sits at $0.3476. If the price goes on to break the first support level at $0.2836, it is likely to go to the next support level at $0.2622. Now, if the price goes above the second support level, the third support stands at $0.2516.
Processa Pharmaceuticals Inc (NASDAQ: PCSA) Key Stats
The company with the Market Capitalisation of 17.27 million has total of 56,644K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -11,850 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -3,440 K.
